Plasmodium vivax and Plasmodium ovale form dormant liver-stage parasites that can reactivate weeks or months after initial infection. These relapses sustain transmission and disease burden even in regions with effective blood-stage control.
Existing radical-cure regimens require G6PD testing due to the risk of oxidative hemolysis. In many endemic regions, testing is unavailable or impractical, resulting in untreated patients, recurrent relapse, and continued transmission.
Without a safe, G6PD-independent liver-stage therapy, malaria elimination efforts remain constrained by logistics rather than biology.
AliquantumRx is developing a G6PD-independent, oral, short-course therapy designed to eliminate liver-stage parasites without hemolysis risk, enabling scalable deployment in endemic settings.